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was stumbled upon (e.g., scurvy), rec­
ognized (e.g., pellagra), or mechanisti­
cally defined (e.g., rickets). One would 
hope that, with the large number of mo­
lecular targets that have been identified 
for chemoprevention [ e.g., Table 2 in 
(])], at least one of them will be equiva­
lent to the examples of nutrient deficien­
cies cited above. Intervention early in 
the disease process of carcinogenesis in 
a highly specific manner based on ration­
al therapeutics will lead to sustainable 
advances at considerably less cost and 
effort than huge, expensive, and lengthy 
trials that use cancer as the end point. 
Although "definitive" large randomized 
trials will continue to be necessary 
to advance the field of chemopreven­
tion, they should be uncommon and 
conducted only after convincing experi­
mental and clinical work has been done 
(7). 
FRANK L. MEYSKENS, JR. 
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